• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors.胸腺瘤中检查点抑制剂的新兴生物标志物
Mediastinum. 2019 Jan 17;3:3. doi: 10.21037/med.2019.01.02. eCollection 2019.
2
[Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)].《胸腺上皮肿瘤临床诊疗中国专家共识（2021年版）》
Zhonghua Zhong Liu Za Zhi. 2021 Apr 23;43(4):395-404. doi: 10.3760/cma.j.cn112152-20210313-00226.
3
Initial Experience of 18F-FDG PET/MRI in Thymic Epithelial Tumors: Morphologic, Functional, and Metabolic Biomarkers.18F-FDG PET/MRI 在胸腺瘤中的初步应用：形态学、功能和代谢生物标志物。
Clin Nucl Med. 2016 Jan;41(1):8-14. doi: 10.1097/RLU.0000000000000946.
4
Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.循环miR-21-5p和miR-148a-3p作为胸腺上皮肿瘤中新兴的非侵入性生物标志物。
Cancer Biol Ther. 2016;17(1):79-82. doi: 10.1080/15384047.2015.1108493.
5
Novel Agents in the Treatment of Thymic Malignancies.胸腺恶性肿瘤治疗中的新型药物
Curr Treat Options Oncol. 2017 Aug 10;18(9):52. doi: 10.1007/s11864-017-0495-8.
6
Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.胸腺癌的副肿瘤和治疗相关免疫并发症。
Curr Treat Options Oncol. 2019 Jun 22;20(7):62. doi: 10.1007/s11864-019-0661-2.
7
The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review.免疫疗法在晚期胸腺上皮肿瘤管理中的作用：一项叙述性综述。
Mediastinum. 2021 Sep;5. doi: 10.21037/med-20-62. Epub 2021 Sep 25.
8
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma.胸腺癌化疗与药物治疗的未来展望
Cancers (Basel). 2021 Oct 19;13(20):5239. doi: 10.3390/cancers13205239.
9
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.基于分子生物标志物的胸腺上皮肿瘤的精准诊断与治疗
Crit Rev Oncog. 2017;22(5-6):507-514. doi: 10.1615/CritRevOncog.2017020577.
10
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.MUC1 在胸腺瘤中的表达：MUC1 可能是区分 B3 型胸腺瘤和胸腺癌的有用标志物。
Virchows Arch. 2011 May;458(5):615-20. doi: 10.1007/s00428-011-1041-x. Epub 2011 Jan 21.

本文引用的文献

1
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.胸腺瘤和胸腺癌中 PD-L1、IDO 和 FOXP3 Tregs 表达模式与生存的关系。
Lung Cancer. 2018 Nov;125:35-42. doi: 10.1016/j.lungcan.2018.09.002. Epub 2018 Sep 7.
2
Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.具有程序性死亡配体 1 表达的胸腺瘤的临床病理特征。
Ann Thorac Surg. 2019 Feb;107(2):418-424. doi: 10.1016/j.athoracsur.2018.08.037. Epub 2018 Oct 9.
3
Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8 T cells on clinical outcome of patients with advanced thymic epithelial tumors.PD-L1、转化生长因子-β表达和肿瘤浸润 CD8 T 细胞对晚期胸腺癌患者临床结局的影响。
Thorac Cancer. 2018 Nov;9(11):1341-1353. doi: 10.1111/1759-7714.12826. Epub 2018 Aug 31.
4
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.帕博利珠单抗治疗难治或复发胸腺癌患者的开放性 II 期临床试验。
J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184. Epub 2018 Jun 15.
5
Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.胸腺癌组织中 PD-L1 的表达与临床病理特征的相关性。
Biomed Res Int. 2018 Apr 23;2018:5830547. doi: 10.1155/2018/5830547. eCollection 2018.
6
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.胸腺瘤和胸腺癌中 PD-L1 和 PD-1 的表达模式、预后价值和肿瘤内异质性。
J Thorac Oncol. 2018 Aug;13(8):1204-1212. doi: 10.1016/j.jtho.2018.04.013. Epub 2018 Apr 24.
7
PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.胸腺瘤中PD-L1免疫表达检测：84例病例研究及文献综述
Ann Diagn Pathol. 2018 Jun;34:135-141. doi: 10.1016/j.anndiagpath.2018.03.012. Epub 2018 Apr 4.
8
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
9
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.四种可靠抗体用于胸腺癌中PD-L1免疫组织化学检测的比较研究
Oncotarget. 2018 Jan 8;9(6):6993-7009. doi: 10.18632/oncotarget.24075. eCollection 2018 Jan 23.
10
The Integrated Genomic Landscape of Thymic Epithelial Tumors.胸腺癌的综合基因组景观。
Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors.

作者信息

Owen Dwight H, Otterson Gregory A

机构信息

Division of Medical Oncology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

出版信息

Mediastinum. 2019 Jan 17;3:3. doi: 10.21037/med.2019.01.02. eCollection 2019.

DOI:10.21037/med.2019.01.02
PMID:35129545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8794308/
Abstract
摘要